Clinical Scorecard: How Widespread GLP-1 Advertising May Shape Body Image

At a Glance

Key Highlights

• A 2025 BMC Public Health study examined 90 FDA-approved GLP-1 advertisements on Facebook and Instagram and found emphasis on emotional and psychological effects, including confidence and transformation.
• Research remains limited on how repeated GLP-1 advertising exposure affects body image and disordered-eating outcomes.
• Clinicians raised concerns in open-ended responses to a NEDA community survey about unavoidable advertising and disordered-eating behaviors among clients.
• A 2026 Body Image article states that weight loss does not reliably produce a healthier psychological relationship with one’s body.
• The article says enhanced telehealth screening and more stringent advertising standards may protect vulnerable populations while avoiding stigma toward people who may benefit from treatment.

Guideline-Based Recommendations

Diagnosis

Management

• NEDA reports that clinicians may coach people with eating disorders or in recovery to limit exposure to material reinforcing comparison, body checking, or restriction.
• The article says enhanced telehealth screening and more stringent advertising standards may protect vulnerable populations.

Monitoring & Follow-up

• The 2026 Body Image article argues that body image warrants attention as a motivator, mediator, and moderator throughout GLP-1 treatment.
• The article urges investigation of whether internet-based GLP-1 access influences reasons for use and treatment participation, especially for appearance-related purposes.

Risks

• The article reports concerns about possible links between advertising, body dissatisfaction, and disordered-eating behaviors, while noting that research on specific effects remains limited.
• Dietitian Lauren Newman says GLP-1 medications carry risks, side effects, and potential downsides.
• The 2026 Body Image article states that weight loss may not resolve body dissatisfaction and may involve heightened monitoring or anxiety about weight regain.

Patient & Prescribing Data

Not reported as prescribing data in the source.

The article describes advertisements for FDA-approved GLP-1 products and compounded, non-FDA-approved versions, often directing consumers to online assessments and possible telehealth prescriptions. Dietitian Lauren Newman says the medications carry risks, side effects, and potential downsides.

Clinical Best Practices

• The 2026 Body Image article argues that body image warrants attention throughout GLP-1 treatment.
• NEDA reports that clinicians may coach people with eating disorders or in recovery to limit exposure to content reinforcing comparison, body checking, or restriction.
• Dietitian Lauren Newman says GLP-1 medications carry risks, side effects, and potential downsides.
• NEDA reports that some people continued to see GLP-1 advertisements after attempting to opt out.

Related Resources & Content

• BMC Public Health (2025) study of 90 GLP-1 advertisements on Facebook and Instagram
• Body Image (2026) article on body image in GLP-1 treatment
• National Eating Disorders Association community survey on social media and eating disorders